Laabs Amanda H. 4
4 · Medline Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Medline (MDLN) CPO Amanda Laabs Receives Large Equity Awards
What Happened
- Amanda H. Laabs, Chief Product Officer of Medline (MDLN), received multiple equity awards and reclassified holdings primarily on 2025-12-16 (with one award reported 2026-03-05). The filing reports a 251,070 share grant plus several derivative "Incentive Units" and RSU-style awards. The aggregate of the reported line items is about 2,313,255 reported shares/units. Most items show no purchase price or economic value in the filing (values = N/A); one small grant of 25,788 shares on 2026-03-05 is listed at $0.00.
Key Details
- Transaction types: all labeled "A" (award/grant/acquisition); includes direct share grant(s), RSUs, and multiple Incentive Units (derivative interests).
- Reported grant line items (high level): 251,070 shares (12/16/2025); 25,788 shares at $0.00 (03/05/2026); plus incentive-unit entries of 251,070; 1,242,391; 189,352; 132,771; and 220,813 (all 12/16/2025).
- Total reported across the lines: ~2,313,255 shares/units (values largely N/A).
- Vesting/convertibility notes from the filing:
- Some securities were reclassified prior to the issuer’s IPO (footnote F1) and were previously reported on a Form 3 (Dec 17, 2025).
- Certain awards are RSUs: 25% vest on June 15, 2026; remaining 75% vest in three equal annual installments beginning March 1, 2027 (F3).
- Incentive Units are "profit interests" with conversion mechanics and vesting schedules; vested Incentive Units can be converted into Common Units according to a formula, and Common Units may be exchangeable for Class A common stock under an Exchange Agreement (F4–F6).
- Specific vesting splits for various incentive awards: 80% vested / 20% vests Oct 21, 2026 (F7); 40% vested / remaining 60% in three equal annual installments from Apr 1, 2026 (F8); 20% vested / remaining 80% in four equal annual installments from Mar 29, 2026 (F9); other Incentive Units vest in five equal annual installments beginning Mar 28, 2026 (F10).
- Class B common shares (where applicable) have no economic value and carry one vote per share; they are tied to Common Units and cancel on exchange for Class A shares (F2).
- Shares owned after the transaction: not specified in the provided excerpt of the Form 4.
- Timeliness: The Form 4 was filed 2026-03-06 for transactions dated 2025-12-16 (and 2026-03-05), indicating the reporting was not timely relative to the transaction dates; some items were already reported on a Form 3 per footnote F1.
Context
- These are awards/grants (not open-market purchases or sales). Awards and incentive units are routine for executives and reflect compensation structure and vesting schedules rather than immediate market bets.
- The Incentive Units are derivative/profit-interest instruments (not simple shares) and convert subject to formulas and vesting; conversion and ultimate economic exposure depend on vesting and the exchange/conversion mechanics described in the footnotes.
- Because most line items list no dollar amount, the filing does not disclose the immediate market value of the grants; check the issuer’s S-1/registration statement and later filings for valuation details.
Insider Transaction Report
Form 4
Medline Inc.MDLN
Laabs Amanda H.
Chief Product Officer
Transactions
- Award
Class B Common Stock
[F1][F2]2025-12-16+251,070→ 251,070 total - Award
Class A Common Stock
[F3]2026-03-05+25,788→ 25,788 total - Award
Common Units of Medline Holdings, LP
[F4][F1]2025-12-16+251,070→ 251,070 total(indirect: See Footnote)→ Class A Common Stock (251,070 underlying) - Award
Incentive Units of Medline Holdings, LP
[F5][F6][F1][F7]2025-12-16+1,242,391→ 1,242,391 total(indirect: See Footnote)Exercise: $15.42→ Class A Common Stock (1,242,391 underlying) - Award
Incentive Units of Medline Holdings, LP
[F5][F6][F1][F8]2025-12-16+189,352→ 189,352 total(indirect: See Footnote)Exercise: $15.23→ Class A Common Stock (189,352 underlying) - Award
Incentive Units of Medline Holdings, LP
[F5][F6][F1][F9]2025-12-16+132,771→ 132,771 total(indirect: See Footnote)Exercise: $19.01→ Class A Common Stock (132,771 underlying) - Award
Incentive Units of Medline Holdings, LP
[F5][F6][F1][F10]2025-12-16+220,813→ 220,813 total(indirect: See Footnote)Exercise: $27.68→ Class A Common Stock (220,813 underlying)
Footnotes (10)
- [F1]These securities were acquired in connection with the reclassification of the interests of Medline Holdings, LP prior to the Issuer's initial public offering (as more fully described in the Registration Statement on Form S-1). These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.
- [F10]These Incentive Units vest in five equal annual installments beginning on March 28, 2026.
- [F2]Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.
- [F3]Represents a grant of restricted stock units ("RSUs"), of which 25% vest on June 15, 2026 and the remaining 75% vest in three equal annual installments beginning on March 1, 2027.
- [F4]Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of the Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.
- [F5]Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.
- [F6](Continued from Footnote 5 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.
- [F7]80% of these Incentive Units have vested, and the remaining 20% vest on October 21, 2026.
- [F8]40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.
- [F9]20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.
Signature
/s/ Nicole Fritz, Attorney-in-Fact|2026-03-06